Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI-30089
- Development stage
- Preclinical
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
IBI-30089 is a preclinical-stage therapeutic candidate developed by Icon Bioscience (now part of EyePoint Pharmaceuticals) for the treatment of proliferative diabetic retinopathy (PDR) and wet age-related macular degeneration (wet AMD). The drug utilizes the proprietary Verisome drug delivery platform, which is a biodegradable, liquid-to-gel system designed for sustained release following intravitreal injection. The program aims to provide long-term therapeutic effects in the posterior segment of the eye, potentially reducing the frequency of injections required for chronic retinal diseases. While the specific active pharmaceutical ingredient has not been publicly disclosed in detail, the candidate is part of a broader effort to apply sustained-release technology to retinal vascular conditions.
- Other names
- IBI-30089IBI30089IBI 30089
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on IBI-30089.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI-30089.